Oncolytics Biotech (ONCY) Cash from Investing Activities (2010 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Cash from Investing Activities of -$6226.0 for Q4 2025, down 44.96% year-over-year from -$11311.0 in Q4 2024, and down 44.96% quarter-over-quarter from -$4295.1 in Q4 2024.
Oncolytics Biotech (ONCY) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Cash from Investing Activities for 15 consecutive years, with -$6226.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 44.96% year-over-year to -$6226.0; the TTM figure through Dec 2025 stood at -$147305.6 (up 15.93% YoY), while the FY2025 annual figure was -$6000.0, up 96.55% from the prior year.
- Cash from Investing Activities declined to -$6226.0 in Q4 2025 per ONCY's latest filing, from -$4295.1 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$4295.1 in Q4 2024 and bottomed at -$15.0 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$1.3 million across 4 years, with a median of -$25750.3 in 2024.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 25452.66% — and 2022, when it soared 95.96%.
- Oncolytics Biotech's Cash from Investing Activities stood at -$59313.0 in 2021, then tumbled by 25172.52% to -$15.0 million in 2022, then surged by 99.97% to -$4295.1 in 2024, then sank by 44.96% to -$6226.0 in 2025.
- Business Quant data shows ONCY's Cash from Investing Activities at -$6226.0 in Q4 2025, -$4295.1 in Q4 2024, and -$23457.7 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6,226.00 |
| Dec 31, 2025 | -6,226.00 |
| Dec 31, 2024 | -4,295.09 |
| Dec 31, 2024 | -4,295.09 |
| Sep 30, 2024 | -23,457.71 |
| Sep 30, 2024 | -23,457.71 |
| Jun 30, 2024 | -113,326.78 |
| Jun 30, 2024 | -113,326.78 |
| Mar 31, 2024 | -34,137.21 |
| Mar 31, 2024 | -34,137.21 |
| Dec 31, 2022 | -14.99 Mn |
| Dec 31, 2022 | -14.99 Mn |
| Sep 30, 2022 | -6,574.08 |
| Sep 30, 2022 | -6,574.08 |
| Jun 30, 2022 | -9,133.65 |
| Jun 30, 2022 | -9,133.65 |
| Mar 31, 2022 | -28,042.96 |
| Mar 31, 2022 | -28,042.96 |
| Dec 31, 2021 | -59,312.98 |
| Dec 31, 2021 | -59,312.98 |